Ascendis Pharma A/S - Ordinary Share (ASND) earnings
ASND earnings moved a median of +0.67% by the close. Quarterly and annual ASND reports and results, each read against the price at its own news timestamp. Back to the ASND overview →
18 measured ASND earnings events.
Where these ASND earnings landedvs 17 measured ASND earnings reactions
| Middle 50% of ASND earnings reactions | -1.66% to +1.88% |
|---|---|
| Median reaction (to close) | +0.67% |
| Measured reactions | 17 |
Point-in-time · zero look-ahead
Half of the 17 ASND earnings events with a measured close landed between -1.66% and +1.88%; 65% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Ascendis Pharma Reports Second Quarter 2026 Financial Results | Press release | -0.15% | -1.66% | |
| Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026 | Press release | +0.66% | +1.45% | |
| Ascendis Pharma Reports First Quarter 2026 Financial Results | Press release | +0.67% | +9.40% | |
| Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 | Press release | +0.86% | -3.68% | |
| Ascendis Pharma Reports Third Quarter 2025 Financial Results | Press release | +3.49% | — | |
| Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 | Press release | +0.00% | +0.67% | |
| Ascendis Pharma Reports Second Quarter 2025 Financial Results | Press release | -3.94% | -4.20% | |
| Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 | Press release | +1.76% | +1.50% | |
| Ascendis Pharma Reports First Quarter 2025 Financial Results | Press release | +7.11% | +2.51% | |
| Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025 | Press release | -0.22% | +2.37% | |
| Ascendis Pharma Reports Third Quarter 2024 Financial Results | Press release | +9.18% | +7.08% | |
| Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 | Press release | -0.16% | -2.41% | |
| Ascendis Pharma Reports Second Quarter 2024 Financial Results | Press release | -2.30% | +1.27% | |
| Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024 | Press release | -0.54% | +0.08% | |
| Ascendis Pharma Reports First Quarter 2024 Financial Results | Press release | -2.79% | -3.35% | |
| Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024 | Press release | -1.53% | -0.80% | |
| Ascendis Pharma Reports Third Quarter 2023 Financial Results | Press release | +0.00% | +0.32% | |
| Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission | Press release | -0.87% | +1.88% |
Keep exploring
More ASND: analyst actions → · SEC filings → · ASND overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| RXI PHARMACEUTICALS CORP (RXII) | 477 | -1.14% | 32% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 477 | -0.11% | 46% |
| Global Cord Blood Corporation (CO) | 471 | 0.00% | 44% |
| NANTKWEST (NK) | 469 | -0.32% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.